Literature DB >> 24797362

Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.

Maria De Salvo1, Lavinia Raimondi1, Serena Vella1, Laura Adesso1, Roberta Ciarapica1, Federica Verginelli1, Antonio Pannuti2, Arianna Citti3, Renata Boldrini3, Giuseppe M Milano1, Antonella Cacchione1, Andrea Ferrari4, Paola Collini5, Angelo Rosolen6, Gianni Bisogno6, Rita Alaggio7, Alessandro Inserra8, Mattia Locatelli9, Stefano Stifani10, Isabella Screpanti11, Lucio Miele2, Franco Locatelli12, Rossella Rota1.   

Abstract

Rhabdomyosarcoma (RMS) is a pediatric myogenic-derived soft tissue sarcoma that includes two major histopathological subtypes: embryonal and alveolar. The majority of alveolar RMS expresses PAX3-FOXO1 fusion oncoprotein, associated with the worst prognosis. RMS cells show myogenic markers expression but are unable to terminally differentiate. The Notch signaling pathway is a master player during myogenesis, with Notch1 activation sustaining myoblast expansion and Notch3 activation inhibiting myoblast fusion and differentiation. Accordingly, Notch1 signaling is up-regulated and activated in embryonal RMS samples and supports the proliferation of tumor cells. However, it is unable to control their differentiation properties. We previously reported that Notch3 is activated in RMS cell lines, of both alveolar and embryonal subtype, and acts by inhibiting differentiation. Moreover, Notch3 depletion reduces PAX3-FOXO1 alveolar RMS tumor growth in vivo. However, whether Notch3 activation also sustains the proliferation of RMS cells remained unclear. To address this question, we forced the expression of the activated form of Notch3, Notch3IC, in the RH30 and RH41 PAX3-FOXO1-positive alveolar and in the RD embryonal RMS cell lines and studied the proliferation of these cells. We show that, in all three cell lines tested, Notch3IC over-expression stimulates in vitro cell proliferation and prevents the effects of pharmacological Notch inhibition. Furthermore, Notch3IC further increases RH30 cell growth in vivo. Interestingly, knockdown of Notch canonical ligands JAG1 or DLL1 in RMS cell lines decreases Notch3 activity and reduces cell proliferation. Finally, the expression of Notch3IC and its target gene HES1 correlates with that of the proliferative marker Ki67 in a small cohort of primary PAX-FOXO1 alveolar RMS samples. These results strongly suggest that high levels of Notch3 activation increase the proliferative potential of RMS cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24797362      PMCID: PMC4010457          DOI: 10.1371/journal.pone.0096238

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  42 in total

Review 1.  Notch signaling: cell fate control and signal integration in development.

Authors:  S Artavanis-Tsakonas; M D Rand; R J Lake
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

2.  Delta-induced Notch signaling mediated by RBP-J inhibits MyoD expression and myogenesis.

Authors:  K Kuroda; S Tani; K Tamura; S Minoguchi; H Kurooka; T Honjo
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

3.  Notch-mediated restoration of regenerative potential to aged muscle.

Authors:  Irina M Conboy; Michael J Conboy; Gayle M Smythe; Thomas A Rando
Journal:  Science       Date:  2003-11-28       Impact factor: 47.728

4.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

5.  Inhibition of Notch signaling induces myotube hypertrophy by recruiting a subpopulation of reserve cells.

Authors:  Magali Kitzmann; Anne Bonnieu; Cédric Duret; Barbara Vernus; Marietta Barro; Dalila Laoudj-Chenivesse; Joseph M Verdi; Gilles Carnac
Journal:  J Cell Physiol       Date:  2006-09       Impact factor: 6.384

6.  Two distinct Notch1 mutant alleles are involved in the induction of T-cell leukemia in c-myc transgenic mice.

Authors:  C D Hoemann; N Beaulieu; L Girard; N Rebai; P Jolicoeur
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

7.  Functional Notch signaling is required for BMP4-induced inhibition of myogenic differentiation.

Authors:  Camilla Dahlqvist; Andries Blokzijl; Gavin Chapman; Anna Falk; Karin Dannaeus; Carlos F Ibâñez; Urban Lendahl
Journal:  Development       Date:  2003-12       Impact factor: 6.868

Review 8.  HES and HERP families: multiple effectors of the Notch signaling pathway.

Authors:  Tatsuya Iso; Larry Kedes; Yasuo Hamamori
Journal:  J Cell Physiol       Date:  2003-03       Impact factor: 6.384

9.  Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis.

Authors:  S J Tapscott; M J Thayer; H Weintraub
Journal:  Science       Date:  1993-03-05       Impact factor: 47.728

10.  Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice.

Authors:  D Bellavia; A F Campese; E Alesse; A Vacca; M P Felli; A Balestri; A Stoppacciaro; C Tiveron; L Tatangelo; M Giovarelli; C Gaetano; L Ruco; E S Hoffman; A C Hayday; U Lendahl; L Frati; A Gulino; I Screpanti
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

View more
  6 in total

Review 1.  The Role of Notch3 in Cancer.

Authors:  Zviadi Aburjania; Samuel Jang; Jason Whitt; Renata Jaskula-Stzul; Herbert Chen; J Bart Rose
Journal:  Oncologist       Date:  2018-04-05

2.  A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.

Authors:  Katherine K Slemmons; Lisa E S Crose; Stefan Riedel; Manuela Sushnitha; Brian Belyea; Corinne M Linardic
Journal:  Mol Cancer Res       Date:  2017-09-18       Impact factor: 5.852

3.  PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.

Authors:  J A Hanna; M R Garcia; J C Go; D Finkelstein; K Kodali; V Pagala; X Wang; J Peng; M E Hatley
Journal:  Cell Death Dis       Date:  2016-06-09       Impact factor: 8.469

Review 4.  Notch signaling in the pathogenesis, progression and identification of potential targets for cholangiocarcinoma (Review).

Authors:  Peeranate Vanaroj; Wanna Chaijaroenkul; Kesara Na-Bangchang
Journal:  Mol Clin Oncol       Date:  2022-01-19

5.  Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma.

Authors:  Terra Vleeshouwer-Neumann; Michael Phelps; Theo K Bammler; James W MacDonald; Isaac Jenkins; Eleanor Y Chen
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

Review 6.  Genetics, epigenetics and redox homeostasis in rhabdomyosarcoma: Emerging targets and therapeutics.

Authors:  Ananya Pal; Hsin Yao Chiu; Reshma Taneja
Journal:  Redox Biol       Date:  2019-01-25       Impact factor: 11.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.